NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-194921

Registered date:20/08/2019

WP-1303 Phase 3 combination study

Basic Information

Recruitment status other
Health condition(s) or Problem(s) studiedprimary open-angle glaucoma, ocular hypertension
Date of first enrollment06/9/2019
Target sample size280
Countries of recruitmentJapan
Study typeINTERVENTIONAL
Intervention(s)Intervention name : WP-1303 INN of the intervention : - Dosage And administration of the intervention : agents for ophthalmic use Control intervention name : placebo INN of the control intervention : - Dosage And administration of the control intervention : agents for ophthalmic use

Outcome(s)

Primary Outcomesafety, efficacy efficacy:intraocular pressure safety:adverse event and adverse drug reaction
Secondary Outcomeefficacy efficacy:intraocular pressure

Key inclusion & exclusion criteria

Age minimum20
Age maximum
GenderBOTH
Include criteriaPatients with POAG or OH. IOP is less than 35 mmHg for both eyes. IOP aftre latanoplost treated is greater than or equal to 18mmHg.
Exclude criteriaPatients who have visual acuity of less than 0.3. Presence of active eye disease (eg., uveitis, ocular infection, severe dry eye). Pregnant women, lactating women or women who desire to be pregnant. Patients who is judged inappropriate to participate in the study by investigator or sub-investigator.

Related Information

Contact

public contact
Name Wakamoto pharmaceutical Co., Ltd. Clinical development
Address 2-2, Nihonnbashi Honcho 2-chome, Chuo-ku Tokyo
Telephone +81-3-3279-0370
E-mail -
Affiliation
scientific contact
Name Wakamoto pharmaceutical Co., Ltd. Clinical development
Address 2-2, Nihonnbashi Honcho 2-chome, Chuo-ku Tokyo
Telephone +81-3-3279-0370
E-mail -
Affiliation